Elicio Therapeutics and Angion Enter into Definitive Merger

 

• Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio’s proprietary lymph node-targeting Amphiphile (AMP) technology
  

• Lead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer
  

• Conference call to be held 8:00 am Eastern Time on Wednesday, January 18

The Elicio and Angion management teams will host a conference call on Wednesday, January 18, 2023, at 8:00 am Eastern Time to discuss the merger. A live webcast of the conference call can be accessed at the “Events & Presentations” page on the Angion website at https://ir.angion.com/events-presentations. A replay will be available on the Angion website at the same link shortly after conclusion of the event.

https://finance.yahoo.com/news/elicio-therapeutics-angion-enter-definitive-100000159.html